Type 2 diabetes (T2D) is a metabolic disorder characterized by insulin resistance and progressive beta-cell dysfunction. Chronic inflammation is now recognized as a central driver of both insulin resistance and beta-cell failure. MSC therapy targets this inflammatory mechanism directly — offering a disease-modifying approach rather than just glucose management.
Why Inflammation Is the Key Target
Adipose tissue and liver in T2D patients release pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1β) that impair insulin receptor signaling, creating insulin resistance. MSCs suppress this systemic inflammatory state, potentially improving insulin sensitivity independent of weight loss or medication adjustment.
Published Evidence
HbA1c and Glucose Control
Multiple Phase I/II trials have demonstrated reductions in HbA1c of 1–2% at 6–12 months post-MSC infusion, without changes in diabetes medication. A 2017 randomized trial in Stem Cells International showed significant HbA1c improvement in MSC-treated T2D patients versus placebo at 12 months (7.9% → 6.8% mean reduction).
Insulin Sensitivity
HOMA-IR scores (a measure of insulin resistance) improved significantly in MSC-treated patients compared to controls, suggesting the mechanism is genuinely targeting insulin resistance rather than just reducing glucose through other pathways.
Beta-Cell Function
C-peptide levels — a measure of beta-cell function — showed modest increases in some trials, suggesting MSCs may reduce beta-cell stress and support residual function. This effect is more pronounced in patients with shorter disease duration.
Who Benefits Most
T2D patients with disease duration under 10 years, HbA1c between 7.5–10%, and without severe end-organ complications (advanced nephropathy, severe neuropathy) tend to show the strongest response. Patients with T2D who also have inflammatory comorbidities (autoimmune conditions, chronic joint disease) often see improvement in both simultaneously.
Combination with Lifestyle
MSC therapy for T2D works alongside — not instead of — dietary and lifestyle optimization. Patients who maintain appropriate nutrition and activity during the 6–12 month post-treatment period show better and more durable outcomes. We provide dietary guidance as part of the post-treatment support program.